Literature DB >> 8979248

Inhibitors of endothelin.

M L Webb1, T D Meek.   

Abstract

With the advent of the first generation of both selective and nonselective endothelin antagonists being a relatively recent event, the manifold therapeutic potentials of these compounds are only now being explored clinically. Undoubtedly, numerous clinical utilities for these compounds will soon be realized.

Mesh：

Substances：

Year:  1997        PMID： 8979248     DOI： 10.1002/(sici)1098-1128(199701)17:1<17::aid-med2>3.0.co;2-w

Source DB:  PubMed          Journal:  Med Res Rev        ISSN： 0198-6325            Impact factor:   12.944


  4 in total

1.  Chemical synthesis of tetracyclic terpenes and evaluation of antagonistic activity on endothelin-A receptors and voltage-gated calcium channels.

Authors:  Jianyu Lu; Angelo Aguilar; Bende Zou; Weier Bao; Serkan Koldas; Aibin Shi; John Desper; Philine Wangemann; Xinmin Simon Xie; Duy H Hua
Journal:  Bioorg Med Chem       Date:  2015-06-27       Impact factor: 3.641

Review 2.  Benefits of Curcumin in the Vasculature: A Therapeutic Candidate for Vascular Remodeling in Arterial Hypertension and Pulmonary Arterial Hypertension?

Authors:  Ke-Xue Li; Zi-Chao Wang; Jeremiah Ong'Achwa Machuki; Meng-Zhen Li; Yu-Jie Wu; Ming-Kai Niu; Kang-Ying Yu; Qing-Bo Lu; Hai-Jian Sun
Journal:  Front Physiol       Date:  2022-04-01       Impact factor: 4.755

3.  Endothelin-1, big endothelin-1, and nitric oxide in patients with chronic renal disease and hypertension.

Authors:  Ivanka Mikulić; József Petrik; Kresimir Galesić; Zeljko Romić; Ivana Cepelak; Monika Zeljko-Tomić
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

4.  Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation.

Authors:  A P Piovezan; P D'Orléans-Juste; G E Souza; G A Rae
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.